厄贝沙坦联合氨氯地平治疗高血压合并糖尿病肾病的临床效果分析

Clinical Effect of Irbesartan Combined with Amlodipine in the Treatment of Hypertension Combined with Diabetes Nephropathy

目的:研究厄贝沙坦联合氨氯地平治疗高血压合并糖尿病肾病的效果。方法:选取2020年1月-2022年1月咸宁市第一人民医院收治的85例高血压合并糖尿病肾病患者,根据身份证末位数字单双数情况分两组,研究组(n=43)采取厄贝沙坦与氨氯地平联合治疗,对照组(n=42)采取厄贝沙坦治疗。比较两组治疗效果、血压、空腹血糖(FBG)、餐后2 h血糖(2 h PBG)、血清尿素氮(BUN)、血肌酐(Scr)、24 h尿蛋白定量(24 h UPr)、不良反应发生情况。结果:研究组治疗总有效率显著高于对照组,差异有统计学意义(P<0.05)。治疗3个月后,两组收缩压、舒张压均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。治疗3个月后,两组FBG、2 h PBG水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。治疗3个月后,两组BUN、Scr、24 h UPr水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:对高血压合并糖尿病肾病患者采取厄贝沙坦联合氨氯地平治疗,可降低血压与血糖水平,促进临床症状缓解,改善肾功能,且安全性高。

Objective:To study the effect of Irbesartan combined with Amlodipine in the treatment of hypertension combined with diabetic nephropathy.Method:A total of 85 patients with hypertension and diabetes nephropathy admitted to the First People's Hospital of Xianning from January 2020 to January 2022 were selected.According to the single or even number of the last digit of the ID card,they were divided into two groups,the research group(n=43)was treated with Irbesartan combined with Amlodipine,and the control group(n=42)was treated with Irbesartan.The treatment effect,blood pressure,fasting blood glucose(FBG),2 h postprandial blood glucose(2 h PBG),serum blood urea nitrogen(BUN),serum creatinine(Scr),24 h urine protein quantification(24 h UPr)and adverse reactions were compared between two groups.Result:The total effective rate of treatment in the research group was significantly higher than that in the control group,the difference was statistically significant(P<0.05).After 3 months of treatment,systolic blood pressure and diastolic blood pressure in the two groups were lower than those before treatment,and the research group were lower than those in the control group,the differences were statistically significant(P<0.05).After 3 months of treatment,the levels of FBG and 2 h PBG in both groups were lower than those before treatment,and the research group were lower than those in the control group,the differences were statistically significant(P<0.05).After 3 months of treatment,the levels of BUN,Scr,and 24 h UPr in both groups were lower than those before treatment,and the research group were lower than those in the control group,the differences were statistically significant(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Irbesartan combined with Amlodipine has a significant effect in the treatment of hypertension combined with diabetes nephropathy,which can reduce blood pressure and blood glucose levels,promote clinical symptom relief,improve renal function,and has high safety.